A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth
Launched by UNIVERSITY OF BIRMINGHAM · Apr 8, 2020
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
The aim of this trial is evaluate the implementation of early detection and the use of the WHO MOTIVE 'first response' treatment bundle for PPH on clinical, implementation and resource use outcomes. The investigators will evaluate the implementation through mixed-methods and carry out a health economic evaluation from the public healthcare system perspective. The investigators will use a multi-country, parallel cluster randomised trial design with a baseline control phase, along with mixed-methods and health economic evaluations. The trial is conducted in secondary level health facilities i...
Gender
FEMALE
Eligibility criteria
- • Cluster: Health facility is the randomisation unit. Health facilities are eligible for inclusion if they have 1000 to 5000 births a year and provide comprehensive obstetric care with ability to perform surgery for PPH. Health facilities are selected based on being administratively and geographically distinct from each other. Pre-existing implementation of early detection or bundled approach are exclusion criteria
- • Research participants: All healthcare providers attending vaginal births at the study facilities.
- • Patients: All verified vaginal births in the study facilities
About University Of Birmingham
The University of Birmingham is a leading research institution in the UK, renowned for its commitment to advancing medical science and improving health outcomes through innovative clinical research. With a strong emphasis on collaboration, the university engages in multidisciplinary studies that leverage cutting-edge technology and expertise across various fields. Its dedicated clinical trial infrastructure supports rigorous investigation and the ethical conduct of research, ensuring that findings contribute meaningfully to the scientific community and public health. Through its initiatives, the University of Birmingham aims to translate research discoveries into tangible benefits for patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Johannesburg, , South Africa
Karachi, , Pakistan
Nairobi, , Kenya
Cape Town, , South Africa
Dar Es Salaam, , Tanzania
Karachi, , Pakistan
Kano, , Nigeria
Colombo, , Sri Lanka
Patients applied
Trial Officials
Arri Coomarasamy, MD
Principal Investigator
University of Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials